Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
Posted
Frank Vinluan (via MedCity News)
Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion.
The post Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M appeared first on MedCity News.
